CULLINAN THERAPEUTICS INC. - COMMON STOCK

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 2 2023 15:41:55 提供 Nasdaq GlobeNewswire

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

24 1 2023 07:00:02 提供 Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 1 2023 16:13:42 提供 Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 12 2022 16:00:00 提供 Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results

14 11 2022 06:00:03 提供 Nasdaq GlobeNewswire

Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors

02 11 2022 07:00:01 提供 Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 11 2022 16:23:46 提供 Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Upcoming Investor Conferences

01 11 2022 06:00:01 提供 Nasdaq GlobeNewswire

Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619

25 10 2022 06:00:01 提供 Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 10 2022 15:50:00 提供 Nasdaq GlobeNewswire

Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference

07 9 2022 07:00:02 提供 Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 9 2022 16:27:22 提供 Nasdaq GlobeNewswire

Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer

15 8 2022 15:57:42 提供 Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results

10 8 2022 06:00:00 提供 Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 8 2022 15:55:00 提供 Nasdaq GlobeNewswire

Cullinan Oncology to Participate in William Blair Biotech Focus Conference

05 7 2022 15:01:00 提供 Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 7 2022 15:38:19 提供 Nasdaq GlobeNewswire

Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417

23 6 2022 07:00:01 提供 Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 6 2022 16:00:00 提供 Nasdaq GlobeNewswire

Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting

31 5 2022 07:00:01 提供 Nasdaq GlobeNewswire